Using blood biomarkers to improve liver transplant immunosuppression
Utility of Biomarkers of Rejection and Kidney Injury in Tailoring Liver Transplant Immunosuppression
This study is looking at how certain blood tests can help doctors create personalized treatment plans for people who have received a liver transplant, making it easier to prevent rejection and protect kidney health.
Quick facts
| Grant type | U01 cooperative agreement |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Northwestern University at Chicago NIH-funded |
| Lab location | 1 site (Chicago, United States) |
| Project ID | NIH-10888310 on NIH RePORTER |
What this research studies
This research investigates how blood biomarkers can help tailor immunosuppressive therapy for liver transplant recipients. By analyzing these biomarkers, the study aims to identify patients at risk of rejection or kidney injury, allowing for personalized treatment plans. The approach involves a multi-center clinical trial where blood samples will be collected and analyzed over time to monitor changes in biomarker levels. This could lead to better management of immunosuppression and improved patient outcomes.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals who have undergone a liver transplant and are currently receiving immunosuppressive therapy.
Not a fit: Patients who have not had a liver transplant or those who are not on immunosuppressive therapy may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective and personalized immunosuppressive therapies for liver transplant patients, reducing the risk of rejection and kidney injury.
How similar studies have performed: Previous studies have shown promise in using biomarkers for managing immunosuppression in transplant patients, indicating that this approach has potential for success.
Where this research is happening
Chicago, United States
- Northwestern University at Chicago — Chicago, United States (Active)
Researchers
- Principal investigator: Levitsky, Josh — Northwestern University at Chicago
- Study coordinator: Levitsky, Josh
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.